Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
SAVE TRIAL |
|
|---|---|
| Problem | Acute MI + LV dysfunction |
| Format | Multicenter, double-blinded, parallel-group, randomized, placebo-controlled trial |
| Treatment | Captopril |
| Control | Placebo |
| Population | 2,231 patients |
| Inclusion criteria | Age 21 years or older MI within prior 3 days New onset LVEF <40% No overt LVF |
| Exclusion criteria | Age >80 Contraindication to ACE inhibitors Symptomatic CHF or HTN requiring ACEi Serum creatinine level >2.5mg/dl Other conditions believed to limit survival Unstable course after infarction |
| Follow-up | Mean 42 months |
| Primary endpoint | All-cause mortality |
| Secondary endpoint(s) | CHF requiring hospitalization or recurrent MI CHF hospitalization CHF requiring ACEi Recurrent MI CV death, CHF requiring ACE inhibitor, CHF hospitalization, or recurrent MI |
| Details | - |
| Brief summary: | |
| PAPER: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE | |
|---|---|
| Date | 3 Sep 1992 |
| Journal | N Engl J Med. 1992 Sep 3;327(10):669-77. |
| Information | Captopril in AMI with EF<40% but no overt CCF -19% reduction in mortality -Independent of age, EF%, prior MI, sex, BP, thrombolytic use, aspirin & beta-blockers (p=0.013) See GISSI-3 for blanket ACEi use post-MI (regardless of EF) |